My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.460 -0.060 (-3.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Forecasting The Future: 4 Analyst Projections For Ocugen
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Why Ocugen Stock Zoomed 12% Higher Today
A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs. 
Via The Motley Fool
Ocugen Shares Are Trading Higher Monday: What's Going On?
Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400. 
Via Benzinga
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
From Ocugen
Via GlobeNewswire
Demystifying Ocugen: Insights From 5 Analyst Reviews
 
Via Benzinga
A Peek at Ocugen's Future Earnings
 
Via Benzinga
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire
Ocugen (OCGN) Q2 Revenue Jumps 20%
Via The Motley Fool
Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows
Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism. 
Via Chartmill
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
Earnings Scheduled For August 1, 2025
 
Via Benzinga
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
From Brodsky & Smith LLC
Via GlobeNewswire
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?
Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics. 
Via Benzinga
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
From Ocugen
Via GlobeNewswire
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial
Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients who currently have no other options. 
Via Benzinga
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen To Present at BIO International Convention 2025
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
From Ocugen
Via GlobeNewswire
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
From Ocugen
Via GlobeNewswire
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts
 
Via Benzinga
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish
CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three... 
Via Stocktwits
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.